HC Wainwright Forecasts ImmunityBio FY2030 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) – HC Wainwright issued their FY2030 EPS estimates for ImmunityBio in a report released on Tuesday, January 20th. HC Wainwright analyst A. Maldonado forecasts that the company will earn $0.68 per share for the year. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to analysts’ expectations of $31.88 million.

A number of other equities analysts have also weighed in on IBRX. Jefferies Financial Group upped their price objective on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. D. Boral Capital reissued a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a report on Tuesday. Piper Sandler upped their price target on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

ImmunityBio Stock Performance

Shares of IBRX stock opened at $6.48 on Wednesday. The stock has a fifty day simple moving average of $2.44 and a two-hundred day simple moving average of $2.49. The firm has a market capitalization of $6.38 billion, a PE ratio of -15.80 and a beta of 0.03. ImmunityBio has a 52-week low of $1.83 and a 52-week high of $7.98.

Institutional Investors Weigh In On ImmunityBio

Several large investors have recently bought and sold shares of IBRX. Vanguard Group Inc. raised its stake in ImmunityBio by 26.8% during the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after purchasing an additional 5,837,898 shares in the last quarter. Armistice Capital LLC purchased a new position in shares of ImmunityBio in the 2nd quarter worth $20,497,000. Heights Capital Management Inc. purchased a new position in shares of ImmunityBio in the 3rd quarter worth $16,152,000. Geode Capital Management LLC increased its holdings in shares of ImmunityBio by 34.7% in the 2nd quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock worth $15,254,000 after buying an additional 1,487,849 shares during the last quarter. Finally, Woodline Partners LP raised its position in shares of ImmunityBio by 53.7% during the 3rd quarter. Woodline Partners LP now owns 5,297,725 shares of the company’s stock valued at $13,032,000 after buying an additional 1,851,854 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: FDA end-of-phase meeting: ImmunityBio said it held a Type B meeting with the FDA and plans to submit additional information within 30 days as part of a potential resubmission path for the ANKTIVA sBLA in papillary non‑muscle invasive bladder cancer — a clearer regulatory route is viewed as materially positive for the drug’s label expansion and commercial prospects. ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® …
• Positive Sentiment: Market coverage reports and investor reaction: Multiple outlets highlight the FDA discussion as the proximate cause of the rally, emphasizing that the agency outlined next steps for resubmission and label expansion — this narrative has driven heavy buying interest. Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA …
• Positive Sentiment: Clinical data momentum: Updated study results for the company’s off‑the‑shelf CAR‑NK / CD19 t‑haNK programs reported durable complete responses in Waldenström lymphoma without chemo or lymphodepletion — positive clinical data can boost longer‑term valuation upside. ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results
• Positive Sentiment: Analyst support: D. Boral Capital reaffirmed a buy rating and published a $24 price target, signaling bullish institutional sentiment that may encourage additional inflows. Benzinga
• Neutral Sentiment: Press and news flow: Multiple outlets (Investing.com, The Pharma Letter, Benzinga, Blockonomi, MSN) are amplifying the FDA and clinical stories — broader coverage increases visibility but doesn’t change fundamentals by itself. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
• Negative Sentiment: High volatility and fundamentals remain mixed: despite the rally, the company is forecast to report negative EPS for the year and the stock has proven highly volatile — some commentators include IBRX on watchlists of speculative or high‑risk healthcare names. That risk could prompt quick profit‑taking if regulatory or data follow‑ups disappoint. Top 3 Health Care Stocks You May Want To Dump In January

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.